Ignite Creation Date:
2025-12-25 @ 3:29 AM
Ignite Modification Date:
2026-02-01 @ 5:14 PM
Study NCT ID:
NCT00058305
Status:
COMPLETED
Last Update Posted:
2013-01-10
First Post:
2003-04-07
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | View |
| None | Nodal Marginal Zone B-cell Lymphoma | View |
| None | Recurrent Adult Diffuse Large Cell Lymphoma | View |
| None | Recurrent Adult Diffuse Mixed Cell Lymphoma | View |
| None | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | View |
| None | Recurrent Grade 1 Follicular Lymphoma | View |
| None | Recurrent Grade 2 Follicular Lymphoma | View |
| None | Recurrent Grade 3 Follicular Lymphoma | View |
| None | Recurrent Mantle Cell Lymphoma | View |
| None | Recurrent Marginal Zone Lymphoma | View |
| None | Recurrent Small Lymphocytic Lymphoma | View |
| None | Splenic Marginal Zone Lymphoma | View |
Keywords: